<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11261">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588380</url>
  </required_header>
  <id_info>
    <org_study_id>07-004153</org_study_id>
    <nct_id>NCT00588380</nct_id>
  </id_info>
  <brief_title>GLP1R Polymorphisms and Response to GLP1</brief_title>
  <official_title>A Pilot Study Examining How Common Genetic Variation in GLP1R Alters Response to GLP1 Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucagon-like Peptide-1 (GLP-1) is an important incretin hormone which acts as a powerful
      insulin secretagogue. Defects in GLP-1 synthesis and secretion are thought to be part of the
      pathogenesis of type 2 diabetes. Furthermore GLP-1 based therapy is an important part of the
      therapeutic armamentarium for the treatment of type 2 diabetes. The GLP-1 receptor (GLP1R)
      is the principal site of action of GLP-1 and GLP-1 receptor agonists like exenatide and
      liraglutide. The gene coding for this receptor, GLP1R, is highly polymorphic and contains
      numerous non-synonymous Single Nucleotide Polymorphisms (nsSNPs) which could potentially
      alter response to endogenous or exogenous GLP-1 or GLP-1R agonists. Indeed there is some in
      vitro data to support this concept. We propose to utilize a hyperglycemic clamp to test the
      insulin secretory response to infused GLP-1 in healthy volunteers to determine the effect of
      genetic variation in GLP1R on response to GLP-1.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Insulin Secretion at 150-180 Minutes.</measure>
    <time_frame>150 - 180 minutes after GLP-1 infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The 180 minute value represents the mean of the values obtained at 150, 160, 170, and 180 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Secretion at 210-240 Minutes</measure>
    <time_frame>210 - 240 minutes after GLP-1 infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The 240 minute value represents the mean of values obtained at 210, 220, 230, and 240 minutes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants recieved GLP-1 intravenously at 0.75 pmol/kg/min for the first hour and then at 1.5 pmol/kg/min for the next hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,</description>
    <arm_group_label>GLP-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-40

          -  fasting glucose concentration of less than 95 mg/dl.

        Exclusion Criteria:

          -  Individuals with a BMI &lt; 19 or &gt; 40 kg/m^2

          -  active systemic illness

          -  medication that can alter gastric emptying, insulin secretion &amp; action

          -  history of abdominal surgery (other than appendectomy or tubal ligation).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Sathananthan A, Man CD, Micheletto F, Zinsmeister AR, Camilleri M, Giesler PD, Laugen JM, Toffolo G, Rizza RA, Cobelli C, Vella A. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care. 2010 Sep;33(9):2074-6. doi: 10.2337/dc10-0200.</citation>
    <PMID>20805279</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <lastchanged_date>December 14, 2011</lastchanged_date>
  <firstreceived_date>December 22, 2007</firstreceived_date>
  <firstreceived_results_date>April 4, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>Insulin Secretion</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy volunteers recruited from Olmsted County, MN.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All participants recieved glucose for 2 hours then Glucagon Like Peptide-1 (GLP-1) intravenously at a rate of 0.75 pmol/kg/min for 1 hour followed by 1.5 pmol/kg/min for the subsequent hour. The study lasted for 240 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>All participants recieved glucose for 2 hours then Glucagon Like Peptide-1 (GLP-1) intravenously at a rate of 0.75 pmol/kg/min for 1 hour followed by 1.5 pmol/kg/min for the subsequent hour. The study lasted for 240 minutes.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="88"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26.3" spread="5.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="88"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Secretion at 150-180 Minutes.</title>
        <description>The 180 minute value represents the mean of the values obtained at 150, 160, 170, and 180 minutes.</description>
        <time_frame>150 - 180 minutes after GLP-1 infusion</time_frame>
        <safety_issue>No</safety_issue>
        <population>all participants completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>C-peptide as a marker of insulin secretion</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Insulin Secretion at 150-180 Minutes.</title>
            <description>The 180 minute value represents the mean of the values obtained at 150, 160, 170, and 180 minutes.</description>
            <units>10^-9 min^-1</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>rs6923761 (1,1) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="104" spread="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>rs6923761 (1, 2) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94" spread="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>rs6923761 (2, 2) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81" spread="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>rs3765467 (1,2) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92" spread="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>rs3765467 (2,2) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="219" spread="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Using the Kruskal-Wallis test (general allelic model), we assessed univariate associations of rs6923761 genotype with Phi Total in the presence of either glucose alone, glucose and 0.75 pmol/kg/min GLP-1 or glucose and 1.5 pmol/kg/min GLP-1 If the p-value for the overall univariate test of association was &lt;0.1, then the associations for specific genotype pairs (e.g.: 1,1 vs. 1,2 or 2,2 vs. 1,1) were also examined using a Mann-Whitney Rank Sum test.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.11</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Secretion at 210-240 Minutes</title>
        <description>The 240 minute value represents the mean of values obtained at 210, 220, 230, and 240 minutes.</description>
        <time_frame>210 - 240 minutes after GLP-1 infusion</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants completing the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All participants recieved glucose for 2 hours then Glucagon Like Peptide-1 (GLP-1) intravenously at a rate of 0.75 pmol/kg/min for 1 hour followed by 1.5 pmol/kg/min for the subsequent hour. The study lasted for 240 minutes.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Insulin Secretion at 210-240 Minutes</title>
            <description>The 240 minute value represents the mean of values obtained at 210, 220, 230, and 240 minutes.</description>
            <units>10^-9 min^-1</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>rs6923761 (1,1) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="152" spread="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>rs6923761 (1,2) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="133" spread="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>rs6923761 (2,2) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112" spread="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>rs3765467 (1,2) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="132" spread="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>rs3765467 (2,2) genotype</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="325" spread="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>All data are presented as means ± SEM. Using the Kruskal-Wallis test (general allelic model), we assessed univariate associations of genotype with ΦTotal</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.09</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of the study (4 hours)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>All participants recieved glucose for 2 hours then Glucagon Like Peptide-1 (GLP-1) intravenously at a rate of 0.75 pmol/kg/min for 1 hour followed by 1.5 pmol/kg/min for the subsequent hour. The study lasted for 240 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a pilot study with limited power to detect / replicate effects. It will require independent replication of study results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Adrian Vella</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-3754</phone>
      <email>vella.adrian@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
